Pharmacotherapy of depression in pregnancy.


Journal Article (Review)

About 20% of pregnant women experience clinical depression. Inadequate treatment of depression has been associated with adverse outcomes in the mother as well as the newborn. Clinicians are often uncertain about pharmacological interventions to treat depressed pregnant women due to concerns regarding fetal exposure to medications. Moreover newer antidepressants with different pharmacological profiles and little data on fetal risk continue to be introduced at a brisk pace. Accumulating data from pharmaceutical registries, cohort studies, toxicology centers, some prospective studies, and case series have permitted certain guidelines for antidepressant use during pregnancy. We review the safety profiles of commonly used antidepressants, discuss clinical decision making based on risk-benefit considerations and make recommendations for pharmacological treatment of depressed women during pregnancy.

Full Text

Duke Authors

Cited Authors

  • Patkar, AA; Bilal, L; Masand, PS

Published Date

  • April 2004

Published In

Volume / Issue

  • 16 / 2

Start / End Page

  • 87 - 100

PubMed ID

  • 15328902

Pubmed Central ID

  • 15328902

Electronic International Standard Serial Number (EISSN)

  • 1547-3325

International Standard Serial Number (ISSN)

  • 1040-1237

Digital Object Identifier (DOI)

  • 10.1080/10401230490453662


  • eng